Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 187,024 | 63,593 | 38,766 | 104,112 | 148,657 |
| Cost of Goods | 15,011 | 12,317 | 12,347 | 8,218 | 20,950 |
| Gross Profit | 172,014 | 51,277 | 26,420 | 95,895 | 127,707 |
| Operating Expenses | 170,434 | 157,972 | 170,271 | 149,469 | 167,599 |
| Operating Income | 1,590 | -106,379 | -143,505 | -53,357 | -38,942 |
| Interest Expense | -24,539 | 27,872 | 21,133 | 83,774 | 265 |
| Other Income | -64,971 | 26,294 | 47,093 | -2,411 | -47,556 |
| Pre-tax Income | -38,841 | -107,957 | -117,545 | -139,542 | -86,763 |
| Income Tax | 1,150 | 1,122 | 247 | 2,723 | 6,278 |
| Net Income Continuous | -39,991 | -109,078 | -117,791 | -142,265 | -93,041 |
| Net Income | $-39,991 | $-109,078 | $-117,791 | $-142,265 | $-93,041 |
| EPS Basic Total Ops | -0.62 | -1.89 | -2.06 | -2.50 | -1.64 |
| EPS Basic Continuous Ops | -0.62 | -1.90 | -2.05 | -2.50 | -1.64 |
| EPS Diluted Total Ops | -0.62 | -1.89 | -2.06 | -2.50 | -1.64 |
| EPS Diluted Continuous Ops | -0.62 | -1.90 | -2.05 | -2.50 | -1.64 |
| EPS Diluted Before Non-Recurring Items | -0.68 | -1.89 | -2.05 | N/A | N/A |
| EBITDA(a) | $6,201 | $-101,368 | $-138,818 | $-48,496 | $-33,641 |